Conversations on Colorectal Cancer

Here to give us a breakdown of what the latest clinical trials are saying about anti-EGFR therapies in left versus right-sided colorectal cancer tumors is Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School.

Here to give us a breakdown of what the latest clinical trials are saying about anti-EGFR therapies in left versus right-sided colorectal cancer tumors is Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School.

Tune in to hear Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School, discussing the clinical presentations of tumor sidedness in colorectal cancer patients and how it affects diagnosis, prognosis, and treatment.

When a patient with metastatic colorectal cancer experiences adverse events like complete obstruction and tumor perforations, it can further complicate an already-difficult disease to manage. That’s why Dr. Putao Cen is here to reveal his key strategies in managing these and other adverse events in metastatic colorectal cancer.

Since colorectal cancer continues to be one of the most common—and lethal—cancers, it should come as no surprise that much research has focused on improving the way we prevent, detect, and treat it, and joining Dr. John Russell to talk about the current and emerging research avenues in colorectal cancer is Dr. Axel Grothey.

In recent years, researchers have been investigating the role of tumor sidedness in metastatic colorectal cancer, and here to walk us through the latest findings and their application to colorectal cancer care is Dr. Axel Grothey.

Since biomarker testing can aid in the creation of individualized treatment plans, Dr. Axel Grothey is here to provide his perspective on the current state of biomarker testing for colorectal cancer and how we can increase biomarker testing practices at the time of diagnosis.

Since colorectal cancer continues to be one of the most common—and lethal—cancers, it should come as no surprise that much research has focused on improving the way we prevent, detect, and treat it, and joining Dr. John Russell to talk about the current and emerging research avenues in colorectal cancer is Dr. Axel Grothey.

In recent years, researchers have been investigating the role of tumor sidedness in metastatic colorectal cancer, and here to walk us through the latest findings and their application to colorectal cancer care is Dr. Axel Grothey.

Since biomarker testing can aid in the creation of individualized treatment plans, Dr. Axel Grothey is here to provide his perspective on the current state of biomarker testing for colorectal cancer and how we can increase biomarker testing practices at the time of diagnosis.